News | August 15, 2013

Mevion Medical Systems Secures $55 Million to Accelerate the Deployment of Its Cancer Treatment Technology

Mevion Medical Systems Funds S250 Deployment

August 15, 2013 — Mevion Medical Systems Inc. has secured $55 million to accelerate the deployment of its revolutionary Mevion S250 Proton Therapy System. The funds were raised from existing equity investors, including Caxton Heath Life Sciences, ProQuest Investments, Venrock and CHL Medical Partners, as well as from debt financing provided by Life Sciences Alternative Funding LLC (LSAF).

Proton particles have the intrinsic ability to deliver a more highly targeted treatment for the management of cancerous tumors and lesions as compared to traditional X-ray radiation therapy. This ability can provide less collateral damage to surrounding healthy tissue, making proton therapy a valuable treatment option for pediatric cancers and high-risk target locations. However, proton therapy has been limited to only a select few institutions because of the high-cost, large space requirements and operational complexities of legacy proton systems. The Mevion S250 is a proton therapy system that has changed this paradigm, delivering the same precise, non-invasive treatment capabilities and advantages of conventional systems but with a significantly reduced size, improved reliability, efficient clinical workflow and lower implementation cost. With a footprint similar to a modern X-ray radiation therapy device, the Mevion S250 brings accessibility, affordability and practicality to proton therapy.

“Mevion was founded to provide cancer centers and patients around the world with cutting-edge proton therapy technology on a scale, size and cost that is accessible and practical for today’s healthcare landscape,” said Joseph K. Jachinowski, chief executive officer of Mevion Medical Systems. “These additional funds will support the growth of our business operations in the U.S. and internationally.”

The Mevion S250 proton therapy system is the only single-room proton therapy system that is cleared by the U.S. Food and Drug Administration (FDA) for clinical use. The first Mevion S250 is installed at the S. Lee Kling Center for Proton Therapy at Barnes Jewish Hospital at Washington University Medical Center in St. Louis, Mo., and is currently undergoing clinical acceptance and commissioning in preparation for patient treatment later this year. With five centers under installation and construction and more than a dozen under planning, Mevion has established itself as a leading proton therapy supplier worldwide

For more information: www.mevion.com

 

Related Content

Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
A model of the new, compact, single-room Varian ProBeam 360 system. The system is an example of the trend in proton therapy toward single-room, smaller systems and away from multi-room treatment centers. #ASTRO18 #ASTRO2018

A model of the new, compact, single-room Varian ProBeam 360 system. The system is an example of the trend in proton therapy toward single-room, smaller systems and away from multi-room treatment centers.

Feature | Proton Therapy | November 01, 2018 | Dave Fornell, Editor
A few of the big takeaways from the American Societ...
Victoria Advisory Committee for Proton Therapy Launched at ASTRO 2018
News | Proton Therapy | October 29, 2018
At the 2018 American Society for Radiation Oncology (ASTRO) annual meeting, IBA announced the launch of the Victoria...
Beaumont Hospital Cancer Institute Performs First Irradiation of Spot Scanning Proton Arc Therapy Plan
News | Proton Therapy | October 25, 2018
IBA announced the first irradiation of a Spot Scanning Proton Arc (SPArc) plan at the Beaumont Health Proton Therapy...
Varian Introduces New ProBeam 360° Proton Therapy System
News | Proton Therapy | October 23, 2018
Varian announced its new single-room proton therapy system, ProBeam 360°, at the 2018 American Society of Radiation...
Amar U. Kishan, M.D., presents data about stereotactic body radiation therapy at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018

Amar U. Kishan, M.D., presents data about stereotactic body radiation therapy at ASTRO 2018.

Feature | Stereotactic Body Radiation Therapy (SBRT) | October 23, 2018 | By Greg Freiherr
With its shorter course of treatment,...
IBA's Proteus system and proton therapy solutions will be discussed at ASTRO 2018. #ASTRO18 #ASTRO #ASTRO2018
News | Proton Therapy | October 19, 2018
October 19, 2018 – IBA (Ion Beam Applications S.A.) is sharing how hospitals can secure performance, investment and t